Mahyar Malekzadeh

Mahyar Malekzadeh

Institute for Cancer Research, Shiraz University of Medical Sciences, Shīrāz, Fārs, Iran
orcid
Always ready to learn! 👨🏻‍🔬

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2011 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
TRThorunn Rafnar
Thorunn Rafnar
SVSita H. Vermeulen
Sita H. Vermeulen
PSPatrick Sulem
Patrick Sulem
GTGudmar Thorleifsson
Gudmar Thorleifsson
KAKatja K. Aben
Katja K. Aben
LKLambertus A. Kiemeney
Lambertus A. Kiemeney
Three genome-wide association studies in Europe and the USA have reported eight urinary bladder cancer (UBC) susceptibility loci. Using extended case and control series and 1000 Genomes imputations of 5 340 737 single-nucleotide polymorphisms (SNPs), we searched for additional loci in the European GWAS. The discovery sample set consisted of 1631 cases and 3822 controls from the Netherlands and 603 cases and 37 781 controls from Iceland. For follow-up, we used 3790 cases and 7507 controls from 13 sample sets of European and Iranian ancestry. Based on the discovery analysis, we followed up signals in the urea transporter (UT) gene SLC14A. The strongest signal at this locus was represented by a SNP in intron 3, rs17674580, that reached genome-wide significance in the overall analysis of the discovery and follow-up groups: odds ratio = 1.17, P = 7.6 × 10−11. SLC14A1 codes for UTs that define the Kidd blood group and are crucial for the maintenance of a constant urea concentration gradient in the renal medulla and, through this, the kidney's ability to concentrate urine. It is speculated that rs17674580, or other sequence variants in LD with it, indirectly modifies UBC risk by affecting urine production. If confirmed, this would support the ‘urogenous contact hypothesis’ that urine production and voiding frequency modify the risk of UBC.

2 September 2015 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
ZKZahra Khoshdel
Zahra Khoshdel
FNFakhraddin Naghibalhossaini
Fakhraddin Naghibalhossaini
KAKourosh Abdollahi
Kourosh Abdollahi
SGSaeid Ghavami
Saeid Ghavami
MSMostafa Moradi Sarabi
Mostafa Moradi Sarabi
Mahyar MalekzadehMahyar Malekzadeh
Mahyar Malekzadeh

23 February 2016 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
APAbbas Pakdel
Abbas Pakdel
Mahyar MalekzadehMahyar Malekzadeh
Mahyar Malekzadeh
FNFakhraddin Naghibalhossaini
Fakhraddin Naghibalhossaini
OBJECTIVE: Liver is the primary site for the metastasis from colorectal cancer (CRC). It has been proposed that carcinoembryonic antigen (CEA) might have an instrumental role in the development of hepatic metastasis from human CRC. The aim of the pre

30 September 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MDMehrnoosh Doroudchi
Mehrnoosh Doroudchi
ZPZahra Ghanaat Pishe
Zahra Ghanaat Pishe
Mahyar MalekzadehMahyar Malekzadeh
Mahyar Malekzadeh
HGHossein Golmoghaddam
Hossein Golmoghaddam
MTMousa Taghipour
Mousa Taghipour
AGAbbas Ghaderi
Abbas Ghaderi
Elevated Serum IL-17A but not IL-6 in Glioma Versus Meningioma and Schwannoma Glioma;meningioma;schwannoma;IL-17A;IL-6;serum; Background: There is a Th1/Th2 cytokine imbalance and expression of IL-17 in patients with brain tumours. We aimed to compare the levels of IL-17A and IL-6 in sera of glioma, meningioma and schwannoma patients as well as in healthy individuals. Materials and Methods: IL-17A and IL-6 levels were measured in sera of 38 glioma, 24 meningioma and 18 schwannoma patients for comparison with 26 healthy controls by commercial ELISA assays. Results: We observed an increase in the IL-17A in 30% of glioma patients while only 4% and 5.5% of meningioma and schwannoma patients and none of the healthy controls showed elevated IL-17A in their sera ($0.29{\pm}0.54$, $0.03{\pm}0.15$ and $0.16{\pm}0.68$ vs. $0.00{\pm}0.00pg/ml$; p=0.01, p=0.01 and p=0.001, respectively). There was also a significant decrease in the level of IL-6 in glioma patients compared to healthy controls ($2.34{\pm}4.35$ vs. $4.67{\pm}4.32pg/ml$; p=0.01). There was a direct correlation between the level of IL-17A and age in glioma patients (p=0.005). Glioma patients over 30 years of age had higher IL-17A and lower IL-6 in their sera compared to the young patients. In addition, a non-significant grade-specific inverse trend between IL-17A and IL-6 was observed in glioma patients, where high-grade gliomas had higher IL-17A and lower IL-6. Conclusions: Our data suggest a Th17 mediated inflammatory response in the pathogenesis of glioma. Moreover, tuning of IL-6 and IL-17A inflammatory cytokines occurs during progression of glioma. IL-17A may be a potential biomarker and/or immunotherapeutic target in glioma cases.

30 September 2012 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
ATAzadeh Andisheh Tadbir
Azadeh Andisheh Tadbir
SPSara Purshahidi
Sara Purshahidi
HEHooman Ebrahimi
Hooman Ebrahimi
BKBijan Khademi
Bijan Khademi
Mahyar MalekzadehMahyar Malekzadeh
Mahyar Malekzadeh
YSYasaman Sardari
Yasaman Sardari
MMP-3 is a proteolytic enzyme of the matrix metalloproteinase family. Protein degradation which is their fundamental action regulates different activities of tumor cell such as their growth, differentiation, apoptosis, migration, invasion, angiogenesis as well as their resistance to the immune system. The aim of this study was to determine MMP-3 serum levels in patients with OSCC and investigate if they correlate with clinicopathological features. Using an ELISA kit, we assessed and compared the circulating levels of MMP-3 in blood serum of 45 oral squamous cell carcinoma patients with 45 healthy control samples. The serum MMP-3 level in OSCC patients was significantly higher (9.45±4.6 ng/ml) than healthy controls (5.9±3.6 ng/ml, p<0.001), especially in females and in older patients. However, there was no apparent correlation in serum MMP-3 concentration with the clinico-pathological features such as tumor location, stage, tumor size, nodal status, distant metastasis, histological grade and smoking. This result suggests that the measurement of serum MMP-3 concentration might be helpful to diagnose OSCC but not to predict prognosis.

1 October 2018
Verified
Journal Article
Open access
PDF file
SFShirin Farjadian
Shirin Farjadian
MTMaryam Tabebordbar
Maryam Tabebordbar
MMMaral Mokhtari
Maral Mokhtari
ASAkbar Safaei
Akbar Safaei
Mahyar MalekzadehMahyar Malekzadeh
Mahyar Malekzadeh
AGAbbas Ghaderi
Abbas Ghaderi
Background: Overexpression of human leukocyte antigen G (HLA-G) and increased plasma levels of solubleHLA-G (sHLA-G) have been reported in different human malignancies, and are believed to be involved in tumor immuneevasion. Objectives: This study was designed to evaluate the expression of HLA-G in tumor tissues and the plasmalevels of sHLA-G in patients with gastrointestinal cancer, and to determine their associations with clinicopathologicalfactors. The link between Helicobacter pylori infection and increased HLA-G expression or sHLA-G levels was alsoinvestigated in patients with gastric cancer. Methods: HLA-G expression was investigated in tumor tissues from 100patients with gastric and colorectal adenocarcinoma using immunohistochemistry test, and plasma levels of sHLA-Gwere measured in 82 patients with ELISA method. The presence of H. pylori genome was investigated in tumortissues from 25 patients with gastric cancer by PCR method. Results: HLA-G expression was observed in 43% ofcolorectal cancers and 34.6% of gastric cancers, and was not related with any of the clinicopathological factors. Therewas a significant correlation between increased sHLA-G level and stage I tumors. Eight of 25 (32%) gastric cancerspecimens were positive for H. pylori, of which 3 samples were positive for HLA-G. Soluble HLA-G levels were abovethe cut-off value in all H. pylori-positive patients. Conclusion: Plasma levels of sHLA-G were significantly increasedin our patients with a sensitivity of 89% and a specificity of 62%. Soluble HLA-G level can be considered a usefulindicator for the early diagnosis of gastric and colorectal adenocarcinoma.